Capricor Therapeutics (NASDAQ:CAPR) Securities Class Action Notice: Investors who Lost Money when Stock Plummeted 64% are Notified to Contact BFA Law by September 28
Bleichmar Fonti & Auld LLP filed a class action lawsuit against Capricor Therapeutics, alleging securities fraud regarding false statements about Deramiocel and clinical data integrity. The suit was triggered by a 64.5% stock drop on July 27, 2026, after FDA documents raised concerns about post-hoc changes to the statistical analysis plan.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.